BMJ
- TANNE JH
Trump's latest pick for FDA head backs president over vaccines and vapes.
BMJ. 2026;394:e100991.
Clin Infect Dis
-
Correction to: Wanted: A Relevant Correlate of Protection for Dengue Vaccines.
Clin Infect Dis. 2026 Sep 30:ciag606. doi: 10.1093.
- SHI MA, Han J, Albahra R, Machicao MF, et al
Hepatitis B Vaccination for Liver Transplant Recipients in the United States: A
National Cohort Study.
Clin Infect Dis. 2026 Sep 29:ciag585. doi: 10.1093.
- KRISHNAN G, Kottilil S
Closing the Hepatitis B Vaccination Gap in Liver Transplant Candidates.
Clin Infect Dis. 2026 Sep 29:ciag586. doi: 10.1093.
J Immunol
- NGUYEN NDNT, Guleed S, Subratheepam S, Marcos-Lopez E, et al
CTH522/CAF01 vaccination elicits clonally related Th17 subsets that mediate
IL-17A-dependent protection against Chlamydia trachomatis.
J Immunol. 2026;215:vkag265.
- ISHIZUKA AS, Garliss CM, Goddu RN, Merolle M, et al
Improving peptide vaccine manufacturability without sacrificing immunogenicity:
substitution of methionine and cysteine with oxidation-resistant isosteres.
J Immunol. 2026;215:vkag232.
- BRAVERMAN J, Monk IR, To MA, Wang N, et al
Live versus killed Listeria monocytogenes immunization differentially programs
Hup-specific CD4+ T cell responses with distinct protective outcomes.
J Immunol. 2026;215:vkag253.
J Infect
- NAZARETH J, Martin CA, Pan D, Barr IG, et al
Ethnic differences in inactivated influenza vaccine immunogenicity in UK
Healthcare Workers: A two-year prospective longitudinal study.
J Infect. 2026 Sep 29:106862. doi: 10.1016/j.jinf.2026.106862.
- GROENVELD MA, Visser DH, Brouwer MC, Jamrozy D, et al
Clinical characteristics, outcomes and molecular epidemiology of group B
streptococcal disease in young infants in the Netherlands.
J Infect. 2026;93:106815.
J Infect Dis
- MUSINGUZI K, Sbarra AN, Bach F, Nankya F, et al
Low birthweight and prematurity, but not malaria chemoprevention, are associated
with reduced pneumococcal vaccine immunogenicity in Ugandan infants.
J Infect Dis. 2026 Sep 28:jiag488. doi: 10.1093.
J Virol
- ZHANG Y, Holly J, Gibbs J, Yewdell JW, et al
Real-time tracking of vaccinia virus entry using a split luciferase
complementation assay.
J Virol. 2026 Sep 29:e0111526. doi: 10.1128/jvi.01115.
JAMA
- ANDERER S
Societies Release Vaccine Recommendations for Respiratory Virus Season.
JAMA. 2026 Oct 2. doi: 10.1001/jama.2026.20006.
N Engl J Med
- HARRIS GH, Sinchi A, Lawler J, Frank M, et al
Andes Virus - A Clinical Review.
N Engl J Med. 2026;395:1310-1317.
Nat Immunol
- LIM K, Dahal A, Lv X, Kim KD, et al
Monocyte-derived galectin-1(hi) cells provide innate immune help in the
generation of functional memory CD8(+) T cells.
Nat Immunol. 2026;27:2102-2116.
Pediatr Rev
- WILLIAMS A, Dehority W
Recognizing a Few of the Vaccine-Preventable Diseases: Part 2.
Pediatr Rev. 2026;47:547-556.
PLoS One
- LIU H, Zhu Z, Liu Y, Wang J, et al
Evaluation of the real-world protective effect of mumps-containing vaccines among
children under 15 years old in Taizhou: A 1:2 matched case-control study.
PLoS One. 2026;21:e0359417.
- SHAH SSAM, Al-Ani HAM, Alwardi MAW, Zehra A, et al
Immunization timeliness and its determinants among young children in Baghdad,
Iraq: A cross-sectional study using documented vaccination cards.
PLoS One. 2026;21:e0359962.
- NEVES RKAD, Bastos LS, Maciel Villela DA, Saraceni V, et al
Rehospitalization due to COVID-19 reinfection in Rio de Janeiro, 2020-2022:
Associations with vaccination status, sociodemographic and clinical factors.
PLoS One. 2026;21:e0332281.
Proc Natl Acad Sci U S A
- OVESON A, Gumel AB
Projected effects of removing school-entry vaccination requirements on measles
transmission in Florida.
Proc Natl Acad Sci U S A. 2026;123:e2610455123.
- HOGARTY MP, Li H, Zhao C, Martella CL, et al
Deletions in variable region 1 of the HIV envelope accelerate V3-glycan bNAb
induction in SHIV-infected rhesus macaques.
Proc Natl Acad Sci U S A. 2026;123:e2620354123.
Vaccine
- RIHS JB, Duval IB, Amorim CCO, Pinto JC, et al
Engineered invasive Lactococcus lactis as an oral vaccine delivery platform is
associated with compartmentalized immune modulation and enhances control of
Leishmania infantum infection.
Vaccine. 2026;93:129218.
- SHICHINOHE S, Li Q, Tanaka H, Anindita J, et al
Cross-clade protection against human H5N1 isolates by a clade 2.3.4.4b HA mRNA
vaccine in mice.
Vaccine. 2026;93:129215.
- DINIZ LLCL, Santos DO, Maffetano CV, Taguchi NT, et al
A multi-antigen chimeric PvCSP-MSP1(19) vaccine induces robust humoral responses
against distinct stages of Plasmodium vivax.
Vaccine. 2026;93:129197.
- GOULD S, Rohde CM, Destexhe E, Tiesjema B, et al
Summary of 2025 Society of Toxicology Workshop "Vaccine Toxicology in the
Post-COVID Era".
Vaccine. 2026;93:129180.
- BANISAEED SR, Rasooli I, Ghazanfari T, Ajdary S, et al
An integrated immunoinformatics and experimental pipeline identifies an
LCL-scaffolded OmpA loop 3 construct as a protective vaccine candidate against
Acinetobacter baumannii.
Vaccine. 2026;93:129205.
- MOZAFFARI F, Aung ET, Soe NN, Wijekoon D, et al
Validation of self-reported mpox vaccination in men who have sex with men.
Vaccine. 2026;93:129193.
- ARROYO L, Raeman R, Iyer SS
Acute immunometabolic reprogramming following clade C HIV immunization in rhesus
macaques.
Vaccine. 2026;92:129115.
- DENG L, Ye X, Chen X, Hu X, et al
Secretory expression of tetrameric neuraminidase enhanced by signal peptide
optimization elicits robust immunity against influenza infection in mice.
Vaccine. 2026;92:129118.
- BAZARJAV P, Erdene-Ochir T, Sandagdorj A, Enkhtuvshin A, et al
One-year antibody kinetics and effectiveness of a BNT162b2 booster after four
primary COVID-19 vaccination regimens in Mongolia.
Vaccine. 2026;93:129179.
- FERNANDEZ-VEIGA L, Elguezabal N, Fuertes M, Geijo MV, et al
Pathological, microbiological and immunological performance of three tuberculosis
vaccine candidates in goats.
Vaccine. 2026;93:129196.
- CHAULAGAIN S, Werner AP, Parish MA, Talukdar SN, et al
Sex differences in vaccine-induced neuraminidase cross-recognition impact H5N1
dissemination to the lower respiratory tract in mice.
Vaccine. 2026;93:129189.
- PATIL DY, Sahay RR, Shete AM, Mohandas S, et al
Development and internal analytical validation of plaque reduction neutralization
test for clinical trial application of Kyasanur forest disease virus vaccine.
Vaccine. 2026;93:129206.
- MONTES CAMINO LM, Aldea M, Martinez C, Garcia-Basteiro AL, et al
Evaluation of the immunogenicity of hepatitis B vaccination in hematopoietic stem
cell transplant recipients vaccinated with a hexavalent vaccine compared with
patients vaccinated with a combined hepatitis A and B vaccine.
Vaccine. 2026;93:129183.
- HUETE-CARRASCO J, Aboagye J, Neple D, McClean S, et al
Cationic surfactant-dependent enhancement of antigen-specific cellular immunity
by a biodegradable nanoparticle vaccine.
Vaccine. 2026;93:129195.
- MWASEBA SL, Burger R, von Fintel D
Beyond disease prevention: rotavirus vaccine rollout and child stunting in
Tanzania.
Vaccine. 2026;93:129210.
- BUTLER TL, Anderson K, Morseu-Diop A, Brotherton JML, et al
Aboriginal and Torres Strait Islander adolescent and parent perspectives on human
papillomavirus vaccination through the School Immunisation Program in Queensland,
Australia: a qualitative study.
Vaccine. 2026;93:129170.
- SEMPERE L, Almenta I, Barrenengoa J, Gutierrez A, et al
Corrigendum to 'Factors predicting response to hepatitis B vaccination in
patients with inflammatory bowel disease' [Vaccine 31 (2013) 3065-3071].
Vaccine. 2026 Sep 28:129140. doi: 10.1016/j.vaccine.2026.129140.
- HYDER S, Melchinger H, Malik F, Kuppalli K, et al
Trust in government institutions and influenza vaccine acceptance among U.S.
adults.
Vaccine. 2026;93:129212.
- SANDERSON K, Robin C, Reynolds R, Hughes G, et al
Measles, mumps and rubella (MMR) vaccination under-recording in primary care in
England: a two-stage cluster survey to inform vaccine optimisation.
Vaccine. 2026;93:129216.
- TSOU TP, Huang YT, Lin CY, Chu PW, et al
Influenza vaccine effectiveness against influenza-related medical visits,
hospitalization and death among adults aged 65 years and older in Taiwan: interim
2024-2025 season result using standard-dose inactivated influenza vaccine.
Vaccine. 2026;93:129165.
- ZHAO JH, Ma QL, Wang WB, Gao PC, et al
Development of a genetically engineered multivalent subunit vaccine against
"struck", "braxy", lamb dysentery, and enterotoxemia in sheep.
Vaccine. 2026;93:129207.
- DING Y, Fu M, Ramachandran R, Yin S, et al
Public availability and completeness of vaccine product labeling in China.
Vaccine. 2026;93:129185.
- JAYASHANKAR L, DeGrace M, Treanor J, Swanson NJ, et al
Protection Before Day One: advancing broadly protective seasonal influenza
vaccines with pandemic coverage.
Vaccine. 2026;93:129188.
- BOUYOU-AKOTET MK, Mawili-Mboumba DP
The Malaria Vaccine Implementation Cascade: From introduction to programme
performance.
Vaccine. 2026;93:129190.
- WILLEMIN T, Guinchard F, Marmey J, Chareyre A, et al
Corrigendum to "Comprehensive characterization of multivalent mRNA vaccines
functionality by flow cytometry and mass spectrometry" [Vaccine 74 (2026)
128180].
Vaccine. 2026 Sep 30:129184. doi: 10.1016/j.vaccine.2026.129184.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016